To investigate the role of Toll-like receptor 2 (TLR2) in uncomplicated acute myocardial infarction (AMI) and in cardiogenic shock (CS).
Introduction
Acute myocardial infarction (AMI) is associated with high morbidity and mortality. 1, 2 Cardiogenic shock (CS) is the leading cause of death in patients with AMI. 3 -7 New evidence suggests that the development of a systemic inflammatory response syndrome (SIRS) not only plays an important role in the pathogenesis of CS but is also a predictor of poor outcome. 8 -10 Toll-like receptors (TLR), expressed in peripheral blood mononuclear cells (PBMCs), play a central role in innate immunity by recognizing invading microbial pathogens and inducing an enhanced proinflammatory cytokine expression such as interleukin-6 (IL6) and tumour necrosis factor alpha (TNFa). 11 A large body of evidence suggests that TLRs seem to be crucial in ischaemia-reperfusion (I/R) injuries, 12 -17 as they have been shown to recognize endogenous proteins released from damaged tissues. 18, 19 In patients with AMI, a rapid increase of TLR4 expression in PBMCs was found not only at the site of plaque rupture in thrombotic material but also in the peripheral circulation. 16, 20 In addition to TLR4, animal studies have also provided evidence for a deleterious role of TLR2 in myocardial ischaemia, demonstrating that survival of TLR2 knockout mice with myocardial infarction was significantly increased compared with wild-type mice. 13 -15,20,21 Consistently, TLR2 deficiency was associated with a smaller infarct size and reduced inflammation. 13, 20, 21 In patients with ACS and early coronary intervention, a local increase of TLR2 on PBMCs was found locally in thrombi of the coronary infarction artery, but not on circulating PBMCs. 16 Recently, murine studies of hypoxia revealed a co-ordinated induction of TLR2 expression. 22 In the present study, we pursued the hypothesis that tissue hypoxia, as it occurs during CS, may modulate TLR2 expression in circulating PBMCs as a late onset of innate immunity. For this purpose, we investigated TLR expression in patients with AMI and CS after a long time period of myocardial I/R injury.
Methods

Study population and clinical study protocol
Fifty patients with AMI, comprising 20 patients with uncomplicated AMI and 30 patients with CS were prospectively enrolled from an intensive care unit (ICU) of a university hospital. All patients received early percutaneous coronary intervention (PCI) on admission. Patients were enrolled immediately after a TIMI-III flow 23 was established by PCI. AMI was diagnosed on the basis of chest pain lasting .30 min, the presence of new ST-segment elevation (at least 0.1 mV in two or more standard leads or at least 0.2 mV in two or more contiguous precordial leads), or/and an increase in a biochemical marker of myocardial necrosis (creatine kinase, troponin T) according to the ESC guidelines. 24 Cardiogenic shock was defined as the simultaneous presence of all the following criteria before or at admission to the ICU: (1) arterial hypotension (systolic arterial blood pressure below 90 mmHg or mean arterial blood pressure below 70 mmHg for 30 min or longer with or without therapy), (2) need for a continuous infusion of inotropic drugs (any dose of dobutamine and norepinephrine), (3) requirement of an intra-aortic balloon pump, and (4) an acute decrease of the left ventricular ejection fraction below 40%. Exclusion criteria were resuscitation, blood transfusion, collagen diseases, advanced liver disease, malignancy, febrile conditions, or any other ongoing infectious diseases. Patients without definite coronary culprit lesions and patients who developed CS later during the ICU stay were also excluded from the analysis. A total of nine patients with CS died during the first 48 h on the ICU. Twenty age-matched healthy volunteers served as control group (healthy controls, HC). The study was approved by the institutional review board and written informed consent was obtained from all subjects. The demographic and clinical data of all patients are presented in Table 1 .
Isolation of human PBMCs
Baseline blood samples were collected immediately after a TIMI-III flow was established by PCI. Peripheral blood mononuclear cells were isolated from arterial blood using Ficoll density gradient. Briefly, whole citrate blood was mixed 1:1 v/v with a solution of phosphatebuffered saline (PBS) and layered onto 0.25 vol. of Ficoll. After centrifugation at 800g for 20 min at room temperature (RT), the layer of mononuclear cells was removed. PBMCs were centrifuged three times in PBS and resuspended in RPMI 1640 with 10% foetal calves serum (FCS) and antibiotics (penicillin/streptomycin).
Isolation of CD14 1 monocytes
Monocytes were isolated from PBMCs by magnetic cell sorting using microbeads in accordance with the instructions of the manufacturer (Dynabeads Monocyte, Invitrogen). Isolated monocytes were bead and antibody free with a purity of CD14 + monocytes of 95%. These cells were either further separated in cytosol and membrane proteins for western blot analysis or proceeded for mRNA isolation. ) and subjected to western blot analysis. Total protein loading was controlled by Poinceau Red staining. Membranes were blocked with 0.1% Western Blocking Reagent (Roche, Mannheim, Germany) and 0.005% goat serum and probed with primary antibodies for TLR2 (ab47840, rabbit polyclonal to TLR2, 1:1000, Abcam, Cambridge, UK) over night at 48C. The goat anti-rabbit peroxidase-labelled secondary antibody was diluted 1:10 000 and incubated for 60 min at RT. Proteins were visualized by enhanced chemiluminescence according to the manufacturer's guidelines (Amersham Pharmacia Biotech, Freiburg, Germany). Autoradiographs were quantified by imaging densitometry and analysed by the 'LabWorks 4.6' Software (LabWorks Image Acquisition and Analysis Software, UVP BioImaging Systems, Cambridge, UK). Data are presented as arbitrary units in per cent of a control sample and normalized to Ponceau Red, unless stated otherwise.
Cell fractionation
mRNA isolation and polymerase chain reactions
After the indicated treatments, culture medium was aspirated and the cells were lysed with 1 mL RNA-Clean and processed according to the manufacturer's protocol to obtain total cellular RNA. Isolated total RNA (2 mg) was reverse transcribed using random primers and MMLV reverse transcriptase for 60 min at 428C and 10 min at 758C. cDNAs were amplified by polymerase chain reaction (PCR) using TaqDNA polymerase. Sequences for sense and antisense primers and PCR conditions (and amplification fragment lengths) were as follows: TLR2_for: GGC CAG CAA ATT ACC TGT GT; TLR2_rev: CAG GAA TGA AGT CCC GCT TA; GAPDH_for: ATG ACA TCA AGA AGG TGG TG; GAPDH_rev: CAT ACC AGG AAA TGA GCT TG. PCR conditions for TLR2: 60 s 948C; 60 s 578C; 90 s 728C; 28 cycles (378 bp). PCR conditions for TLR2: 60 s 948C; 60 s 608C; 90 s 728C; 30 cycles (182 bp). TLR2 mRNA expression levels were normalized to GAPDH.
Hypoxia chamber
PBMCs from healthy volunteers were placed in RPMI 1640 10% faetal calf serum (FCS) medium that had been pre-equilibrated with 5% CO 2 /95% N 2 for 6 h. Cells were then placed in a Labotect incubator , and patients with cardiogenic shock secondary to myocardial infarction (n ¼ 30). The mean fluorescence intensity was normalized to healthy control expression and expressed as the fold increase over controls. ANOVA was performed (P-value).
C42 (MidAtlanticDiagnostics, Gö ttingen, Germany) and exposed to hypoxia (5% CO 2 , 94% N 2 , 1% O 2 ) for 2 -24 h followed by reoxygenation for 22 -0 h. The pH of the medium remained unchanged during hypoxia and reoxygenation. Measurements of supernatant pH, lactate, and pO 2 were performed in blood gas analyses tubes 'safe PICO Aspirator' on ABL800FLEX radiometer (Radiometer Medical ApS, Bonn, Germany). PBMCs were harvested at the times noted in the figures and further proceeded for flow cytometry or Dynabead isolation of CD14 + monocytes.
Procalcitonin measurements
At admission baseline procalcitonin (PCT) was measured in serum probes using the PCT-sensitive Kryptor assay from BRAHMS (Hennigsdorf, Germany). The assay sensitivity was marked by 0.06 mg/L. According to the manufacturer's protocol, a cut-off of PCT . 0.5 mg/L is postulated for a high risk for a potential bacterial infection.
Materials
Leupeptin, PMSF, PFA, aprotinin, and penicillin/streptomycin were purchased from Sigma Aldrich (Deisenhofen, Germany). Rabbit polyclonal against the extracellular domain of human TLR2 was from Abcam (ab47840, Cambridge, UK) and was used for western blotting. HRP-conjugated goat-anti-rabbit secondary antibodies were from Sigma (Deisenhofen, Germany). The following monoclonal antibodies were used for FACS analysis: anti-CD14-PE-Cy5 (Beckman Coulter, Krefeld, Germany), anti-TLR2-FITC (Abcam ab59711, Cambridge, UK), anti-TNFa-FITC (BD Biosciences, Heidelberg, Germany), and anti-IL6-PE (BD Biosciences, Heidelberg, Germany). Ficoll was purchased from Biochrom (Biocoll Separating Solution, Biochrom, Berlin, Germany), RPMI 1640 medium, and FCS was provided by Gibco/Invitrogen (Karlsruhe, Germany). TaqDNA polymerase and nucleotides were purchased from Sigma. MMLV reverse transcriptase and RNA-Clean were obtained from Gibco. All other substances used were from Sigma, unless specified otherwise.
Statistical analyses
Statistical analyses were performed using StatView (SAS Institute Inc., Cary, NC, USA). Data are expressed as the mean + SEM unless otherwise stated. A two-sided P , 0.05 was considered significant. Normal contribution of data was tested by Kolmogorov -Smirnov and Lilliefors. As all parameters were distributed normally, data were compared between two groups using the unpaired t-test and correlations were 
Results
Healthy control and patient characteristics
Demographic data and baseline characteristics are shown in Table 1 . The CS group and the AMI group were age matched. There were no significant differences between the two groups regarding risk factors such as smoking, hypertension, hypercholesterolaemia, diabetes mellitus, and regarding previous medication but statins. Previous statin medication was more frequent in the CS group than in the AMI group (70% in CS vs. 40% in AMI). All patients received PCI on admission. Patients with CS shock had lower ejection fraction, lower cardiac index, lower SVO2 levels, and higher lactate levels compared with AMI patients. Furthermore, patients with CS had substantial circulatory assistance with vasopressors, inotropes, and intra-aortic balloon pumps.
TLR2 expression on circulating monocytes
FACS analysis ( Figure 1A ) demonstrated that the expression of TLR2 on CD14 + monocytes was significantly increased in patients with AMI compared with HC (111.1 + 8.2 vs. 66.9 + 1.5 MFI, P , 0.001, Figure 1B , Table 2 TLR2 up-regulation in cardiogenic shock
Intracellular cytokine expression in monocytes
The spontaneous cytokine production in CD14 + monocytes was measured by intracellular cytokine staining by flow cytometry. TNFa expression in monocytes was significantly increased in patients with CS (20.6 + 5.9%) compared with patients with uncomplicated AMI (4.3 + 1.6%, P ¼ 0.004, Figure 2A , Table 2 ). Furthermore, the intracellular IL6 expression was significantly increased in CS (20.6 + 6.2%) compared with AMI (5.5 + 1.6%, P ¼ 0.032, Figure 2B , Table 2 ). However, no differences in spontaneous monocytic cytokine production were observed between patients with AMI and HC (Figure 2A and B) .
Association of TLR2 expression with procalcitonin
At admission, none of our study patients suffered from a known active infection nor showed any clinical signs of an infectious disease. Nevertheless, 18 of all 50 included patients had elevated PCT levels (.0.5 mg/L) at enrolment. However, there was no difference in the mean TLR2 expression in patients with elevated PCT compared with the group with normal PCT (120.3 + 9.1 vs. 127.8 + 5.2, P ¼ 0.448, Figure 3 ). In the study population, no correlation was found between the TLR2 expression and PCT levels.
Association of TLR2 expression with symptom to reperfusion time and parameters for tissue hypoxia
There was no significant difference with regard to time delay from symptoms to PCI-mediated reperfusion of the infarct vessel between the AMI (9.3 + 1.8 h) and the CS group (9.3 + 1.3 h, P ¼ 0.996), nor between CS survivors and non-survivors (9.0 + 1.4 vs. 9.9 + 2.6 h, P ¼ 0.740, Table 1 ). TLR2 expression on monocytes showed a significant and strong correlation with symptom to reperfusion time in the whole study population (r 2 ¼ 0.706, P , 0.001, n ¼ 50, Figure 4 ).
Additionally, there was a significant positive correlation between TLR2 density on monocytes and serum lactate levels (r 2 ¼ 0.262, Figure 5A ) and an inverse correlation between TLR2 and mixed venous oxygen saturation (r 2 ¼ 0.209, Figure 5B ), both indirect parameters for tissue oxygen lack and anaerobic metabolism. Subsequently, a multiple regression analysis was performed including symptom to reperfusion time and other factors known or thought to have an impact on TLR2 expression (i.e. mixed venous oxygen saturation, lactate, PCT, troponin levels, and ejection fraction) in order to investigate if the observed difference in TLR2 expression between myocardial infarction and CS is independent from these parameters. In this analysis, only symptom to reperfusion time (P , 0.0001) and mixed venous oxygen saturation (P ¼ 0.026) were significant predictors of an increased TLR2 expression (Table 3) , whereas the group (AMI vs. CS) was not (P ¼ 0.983).
Hypoxia-induced TLR2 expression in PBMCs and monocytes in vitro
PBMCs from healthy volunteers (n ¼ 20) were exposed for up to 24 h to either hypoxia alone ( Figure 6 ). The pH of the culture medium showed no significant difference between hypoxiaexposed and control PBMCs for up to 12 h of culture, while supernatant lactate levels increased significantly starting after 6-12 h of hypoxia. Throughout hypoxygenation, partial oxygen pressure (pO 2 ) was kept stable at about 40 mmHg; pO 2 in the control medium was about 140 mmHg.
Hypoxia time-dependently increased TLR2 expression on monocytes starting after a period of 6 h and reaching a maximum after 12 h of culture (baseline: 66.9 + 1, 6 h: 85.6 + 2.6 MFI, 12 h, P , 0.0001, Figure 6 ). Therefore, hypoxia had stimulatory effects of the TLR2 surface expression on CD14
+ monocytes with an EC 50 value of 6 h and a maximum of inducible TLR2 expression after 12 h ( Figure 6 ). These hypoxia-mediated effects were confirmed by cell fractionation and western blotting of isolated CD14 + monocytes from healthy volunteers (Figure 7) . Additionally, TLR2 mRNA levels in isolated monocytes were significantly increased after 2 h of hypoxia, indicating transcriptional activation (P ¼ 0.002, Figure 8 ). TLR2 up-regulation in cardiogenic shock
Discussion
TLRs play a crucial role in innate immunity as the first defence system not only against pathogen-associated molecular patterns in infectious diseases but also against damage-associated molecular patterns in I/R injuries. 12, 14, 18 Previous studies concentrated on the role of TLRs in the myocardial I/R injury found an early onset of TLR4 expression on PBMCs in coronary thrombi and in the peripheral circulation 16 and TLR4 expression reached its peak values within 2 h in reperfusion states or 6 h in non-reperfusion states. 26 Furthermore, the TLR2 expression was locally elevated in coronary thrombi but not systemically. 16 In animal models of myocardial I/R, TLR2 signalling also seems to be involved in a deleterious course. 13, 15, 20, 21, 27, 28 Accordingly, TLR2-deficient mice had less fatal arrhythmias, 28 less ventricular remodelling, 21 and a higher survival rate compared with wild-type mice. TLR2 has been postulated as being essential for the sensing of oxidants during inflammation. 29 Reperfusion-induced myocardial injury is associated with an accumulation of reactive oxygen species (ROS). 30 Activation of TLR may trigger ROS generation, 31 and TLR2 deficiency is associated with a smaller infarct size and reduced reperfusion-induced production of ROS. 13, 15 Recently, murine studies of hypoxia revealed a co-ordinated induction of TLR2 expression. 22 We demonstrated for the first time that hypoxia leads to a timedependent increase in TLR2 expression in CD14 + monocytes from healthy volunteers. Therefore, hypoxia had stimulatory effects on the TLR2 expression on monocytes with an EC 50 of 6 h and a maximum of inducible TLR2 expression after 12 h. These results obtained by FACS analysis were confirmed on the protein level by cell fractionation and subsequent western blotting as well as on the mRNA level, indicating transcriptional activation. An increasing duration of myocardial ischaemia is frequently associated with clinical signs of centralization, organ hypoperfusion, and tissue hypoxia and consecutively with a SIRS. We pursued the hypothesis that tissue hypoxia in AMI and CS may modulate TLR2 expression on circulating PBMCs as a late onset of innate immunity. For this purpose, we investigated TLR expression in patients with AMI and CS after a long time period of myocardial ischaemia.
In the data presented herein, we observed an increase of TLR2 expression on PBMCs in the peripheral circulation in AMI which was even further increased in the setting of CS. Furthermore, significant correlations of TLR2 expression with symptom to reperfusion time, serum lactate levels, and mixed venous oxygen saturation were found. Interestingly, in a multiple regression analysis, symptom to reperfusion time and mixed venous oxygen saturation, both being indirect indicators for tissue hypoxia, were shown to be independently associated with TLR2 expression. Of note, the classification of groups AMI vs. CS in the view of haemodynamics was not independently associated with TLR2 expression. These findings support our hypothesis that severeness of tissue hypoxia, clinically manifested by cool extremities and vital organ hypoperfusion and triggered by compensatory mechanisms of vasoconstriction or vasopressors, plays a key pathophysiological role in up-regulation of TLR2 on circulation PBMCs and in ongoing inflammatory response such as SIRS.
Increased numbers of circulating monocytes in AMI have been described before 32 -34 and may promote the development of heart failure. 33 As shown by our data, not only the absolute number of monocytes but also the number of monocytes expressing TNFa and IL6 were significantly increased in CS. These findings support the role of monocytes as relevant production site of cytokines and point out an additional mechanistic explanation for the increased plasma levels of TNFa and IL6 in AMI/CS. It has been shown that proinflammatory cytokines, notably IL6 and TNFa, are elevated in AMI patients compared with healthy subjects 8, 9, 35 and that plasma levels of these cytokines even further increase in CS. 8 However, the production site of these cytokines remained unclear. We investigated spontaneous monocytic cytokine expression in AMI and CS and confirmed the increase of IL6 and TNFa in AMI/CS patients compared with HC on monocyte level. IL6 is known to be the main cytokine associated with TLR2 activity 36 and seems to be implicated in myocardial injury and reperfusion. 36, 37 These results implicate that proinflammatory cytokines known to be elevated in the setting of AMI/CS might at least partly derive from circulating monocytes and that TLR2 on the surface of monocytes might be involved in this increase. However, some limitations of this study should also be considered. The average symptom to reperfusion time in our patients (AMI/CS) was considerably long (mean 9.3 h). Previous studies showed that early revascularization was not associated with an increased TLR2 expression on circulatory PBMCs 16 and TLR2 response decreased after PCI. 36 These findings underline the importance of an early revascularization in patients with AMI/CS. Interleukin-6 and TNFa might also be induced by some other inflammation triggering receptors which were not investigated in this study. Furthermore, we cannot exclude the possibility that IABP therapy in CS might have influenced TLR2 expression levels, as there are no reports about this so far. However, a recent study of Prodzinsky et al. 38 found no effects of IABP therapy on inflammation parameters such as IL6 levels. Then again, catecholamines are regarded as anti-inflammatory agents suppressing cytokine production. 39, 40 Thus, we cannot exclude the possibility that the observed cytokine expression in our CS patients might have even been attenuated by catecholamine therapy. The same applies to the monocytic TLR2 expression and the higher number of patients with previous statin medication in the CS group (70% vs. 40% in the AMI group), as statins are known to down-regulate cytokine and TLR expression. 35, 41, 42 In summary, our data show that TLR2 expression on circulating monocytes might be relevant in patients with AMI and subsequent CS by increasing proinflammatory cytokines involved in I/R injury. Ischaemia/tissue hypoxia itself seems to be responsible for TLR2 up-regulation in this pathological setting. Immunotherapeutic intervention strategies targeting TLR2 may be beneficial to CS patients. + monocytes from healthy volunteers. Toll-like receptor 2 mRNA expression is in arbitrary units normalized to GAPDH. n ¼ 6 per time point. t-Test was performed (P-value).
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